Standards for clinical trials for treating TB

Publication Date

12-1-2023

Document Type

Article

Publication Title

International Journal of Tuberculosis and Lung Disease

Abstract

B A C K G R O U N D: The value, speed of completion and robustness of the evidence generated by TB treatment trials could be improved by implementing standards for best practice. M E T H O D S: A global panel of experts participated in a Delphi process, using a 7-point Likert scale to score and revise draft standards until consensus was reached. R E S U L T S: Eleven standards were defined: Standard 1, high quality data on TB regimens are essential to inform clinical and programmatic management; Standard 2, the research questions addressed by TB trials should be relevant to affected communities, who should be included in all trial stages; Standard 3, trials should make every effort to be as inclusive as possible; Standard 4, the most efficient trial designs should be considered to improve the evidence base as quickly and cost effectively as possible, without compromising quality; Standard 5, trial governance should be in line with accepted good clinical practice; Standard 6, trials should investigate and report strategies that promote optimal engagement in care; Standard 7, where possible, TB trials should include pharmacokinetic and pharmacodynamic components; Standard 8, outcomes should include frequency of disease recurrence and post-treatment sequelae; Standard 9, TB trials should aim to harmonise key outcomes and data structures across studies; Standard 10, TB trials should include biobanking; Standard 11, treatment trials should invest in capacity strengthening of local trial and TB programme staff. C O N C L U S I O N: These standards should improve the efficiency and effectiveness of evidence generation, as well as the translation of research into policy and practice.

First Page

885

Last Page

898

Link to Full Text

Share

COinS